PDCD1 and non-small cell lung carcinoma: For example, high levels of serum metabolite (e.g hypoxanthine and histidine) were associated with improved progression-free survival and may serve as predictive biomarkers of response to PD-1 blockade therapy in advanced NSCLC patients (71).